SOEDAK2009 --- PREPARE FOR THE LONG RUN

TABLE: Inhalte   Printer Friendly

 Search
  Show all  Advanced Search 
    

First  Previous  1  2  3  4  5  6  7  8  9  10  11-15  Next  Last       Records 141 to 160 of 285
Titel (*)
Autor (*)
  
Efficient suppression of minority quasispecies of drug-resistant viruses present at primary HIV-1 infection by boosted protease inhibitor containing ART
Karin J Metzner1, Pia Rauch2, Viktor von Wyl1, Herbert Kuster1, Jürg Böni3, Rainer Weber1, Huldrych F Günthard1
 View
Efficacy and safety of 48 weeks maintenance with once-daily ATV vs ATV/r in suppressed patients after induction with ATV/r
J-F Delfraissy1, S Moreno2, J Sanz-Moreno3, G Carosi4, V Pokrovsky5, A Lazzarin6, G Pialoux7, A Balogh8, E Vandeloise8, I Scheirich9
View
Low nadir CD4 count predicts failure of LPV/r monotherapy (MOST) due to unexpectedly high failure rate in monotherapy arm
Christine Gutmann1, Milos Opravil2, Christoph Fux3, Hansjakob Furrer3, Laurent-Arthur Decosterd4, Matthias Cavassini4, Sabine Yerly5, Bernard Hirschel5,
 View
Cost effectiveness analysis of atazanavir versus lopinavir in the treatment of naïve HIV patients in Germany
Per-Olof Thuresson1, Iris Scheirich2, Aljoscha S Neubauer2, Bart Heeg1
 View
Vergleich der Kosten-Nutzen-Relation verschiedener Proteaseinhibitoren bei der Erstlinien-Therapie von HIV-Patienten unter Anwendung der vom IQWIG vorgeschlagenen Methode der Effizienzgrenze
Verena Donatz1, Erik Smets2, Andrew Hill3, Matthias Stoll4
 View
Efficacy and safety by baseline HIV-RNA and CD4-count in treatment-naive patients treated with Atazanavir/r and Lopinavir/r in the CASTLE study
J Uy1, R Yang1, A Thiry1, J Absalon1, A Farajallah1, J Maa1, E Grützner2, I Scheirich2, D McGrath1
 View
Susceptibility of diverse HIV-1 patient isolates to the maturation inhibitor, bevirimat, is setermined by clade-specific polymorphisms in Gag CA-SP1
Thomas Klimkait1, Karl Salzwedel2, Severine Louvel1, M Sakalian2, M Reddick2, C Finnegan2, D Martin2, S Mc Callister2, Francois Hamy1, G Al
 View
Once-daily draunavir used in routine clinical care produces trough Darunavir-drug-concentrations in excess of 30x the protein-corrected (PC)EC50 for wild-type HIV
Claire Robertson1, A. N. Jayasuriya1, C. Smith2, N. Dufty1, A. Berry1, C. Stradling1, Steve Taylor1
 View
Lopinavir/ritonavir plus atazanavir in comparison to lopinavir/ritonavir plus nucleoside analogues (zidovudin plus lamivudin) - the LORAN-trial, A Phase III-study
Kai Ulbricht1, Matthias Stoll1, Georg M. Behrens1, Bernd Salzberger2, Heiko Jessen3, Arne Jessen3, Birger Kuhlmann4, Hans Heiken4, Andreas Trein5
View
Long term outcome of 8 infants, which started treatment with 2 NRTI + Nelfinavir in the first year of life
Bernd Buchholz1, Steffen Hien1, Matthias Beichert1, Matthias Dürken1, Horst Schroten1
 View
Health-related quality of life (HRQoL) improvement in antiretroviral-naive HIV-infected patients on atazanavir/r or lopinavir/r regimens: week 24 results from AI424138
J Su1, J Absalon1, M Mancini1, U Iloeje1, N Strobl2, I Scheirich2, D McGrath1
 View
Gender differences in ART-naive patients initiating a lopinavir/ritonavir-based regimen. 48 week data from the German STAR and STELLA cohorts
Christine Koegl1, Axel Baumgarten2, Bernhard Bieniek3, Stefanie Holm4, Martin Hower5, Hans Jaeger6, Thomas Lutz7, Markus Mueller8, Wolfgang Schmidt
View
Starting a Lopinavir/r-based regimen in ART-naive patients improves quality of life. 48-week data from the German STAR and STELLA cohorts
Christine Koegl1, Axel Baumgarten2, Bernhard Bieniek3, Stefanie Holm4, Martin Hower5, Hans Jaeger6, Thomas Lutz7, Markus Mueller8, Wolfgang Schmidt
View
Safety analysis of darunavir/r (DRV/r): combined data from randomised Phase II and Phase III studies
Gerd Fätkenheuer1, Keikawus Arasteh2, Johannes Bogner3, Frank-Detlef Goebel4, Thomas Harrer5, Hans Jäger6, Jörg-Andres Rump7, Dieter Schuster8<
 View
German cost-efficacy analysis to achieve full virological suppression for treatment experienced HIV infected patients in the DUET trials
Matthias Stoll1, Verena Donatz2, Silas Martin3, Andrew M Hill4
 View
HIV RNA levels six months after antiretroviral therapy initiation predict subsequent survival and retention of HIV-1-infected individuals in Sub-Saharan Africa
Maria Cristina Marazzi1, Leonardo Palombi2, Ersilia Buonomo2, Paola Scarcella2, Giovanna Paturzo3, Anna Maria Doro Altan2, Susanna Ceffa3, Dieter Wanderlein4,
View
Retrospektive Datenerhebung über den Zeitpunkt des Therapiebeginns bei HIV positiven Frauen in zwei Zentren Deutschlands von 1995-2008
Ivanka Krznaric1, Alexander Zoufaly2, Sandra Hertling3
 View
Antiretrovirale Therapie bei einem extremen Frühgeborenen
David Endress1, Richard Linde2, Doris Fischer3, Elisabeth Förster-Waldl4, Wolfhart Kreuz2, Andreas Lischka1, Christoph Königs2
 View
Atazanavir plasma concentrations substantially decreased in HIV-1 infected adults taking concomitantly methadone oral solution in a daily observed therapy
Annette Haberl1, Christoph Stephan1, Manfred Mösch2, Gabi Nisius1, Tessa Lennemann1, Pavel Khaykin1, Michael Kurowski3, Schlomo Staszewski1, Reinhard Bro
 View
Pharmacokinetics and dose selection of etravirine (ETR) in HIV-infected children between 6 and 17 years, inclusive
Christoph Königs1, Cornelia Feiterna-Sperling2, Susanna Esposito3, Carlo Giaquinto4, Thomas Kakuda5, Rekha Sinha6, Rebecca Mack5, Katrie Janssen6,
View